Monday, April 27, 2015

Health Research: Gene-editing technique offers hope for hereditary diseases ♦ Non-alcoholic fatty liver disease ♦ TG1050, shows early signs of potential for chronic hepatitis B cure

Gene-editing technique offers hope for hereditary diseases Scientists have used molecular "scissors" to eliminate mitochondrial mutations in eggs and embryos. They are now investigating the possibility of translating this technology to the clinic in human eggs and embryos
Non-alcoholic fatty liver disease shown to affect the development of coronary artery calcification New data show that non-alcoholic fatty liver disease plays a role in the early stages of coronary atherosclerosis and in its more severe form it can also promote the development of coronary artery calcification.
Long-term therapy with ETV or TDF demonstrates positive 5-year survival in patients with chronic HBV Data show that the long-term use of entecavir or tenofovir results in excellent five-year survival for Caucasian patients with chronic hepatitis B, with more than 95 percent of patients surviving at five years and a significant proportion of deaths coming from liver-unrelated causes.
Novel immunotherapeutic, TG1050, shows early signs of potential for chronic hepatitis B cure A novel immunotherapeutic in early development for chronic hepatitis B , has been shown to reach the clinical goals that are considered to be the hallmarks of a cure for CHB.
Investigational anti-diabetic may offer potential for management of nonalcoholic fatty liver New research demonstrates that remogliflozin etabonate, an investigational drug in type 2 diabetes, is a potential treatment option for the management of patients with nonalcoholic steatohepatitis and non-alcoholic fatty liver disease.

No comments:

Post a Comment